Successful use of the impella device in giant cell Myocarditis as a bridge to permanent left Ventricular mechanical support

Texas Heart Institute Journal

Volumn 38, Issue 4, 2011, Pages 437-440

  Suradi, Hussam ^a   Breall, Jeffrey A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune diseases complications drug therapy; Disease progression; Equipment design; Giant cells drug effects pathology; Heart failure immunology pathology; Heart assist devices; Hemodynamics physiology; Left; Myocarditis diagnosis epidemiology physiopathology therapy; Treatment outcome; Ventricular dysfunction

Indexed keywords

ACUTE LUNG INJURY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTIFICIAL VENTILATION; AUSCULTATION; CARDIOGENIC SHOCK; CASE REPORT; CHEST TIGHTNESS; CHILL; DISSEMINATED INTRAVASCULAR CLOTTING; DYSPNEA; ENDOTRACHEAL INTUBATION; FEMALE; FEVER; HEART ATRIUM FIBRILLATION; HEART RIGHT VENTRICLE FAILURE; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANTATION; INTERSTITIAL MYOCARDITIS; KIDNEY FAILURE; LEFT VENTRICULAR ASSIST DEVICE; LIVER FAILURE; LUNG EDEMA; MALAISE; MYOCARDITIS; RESPIRATORY DISTRESS; REVIEW; SINUS TACHYCARDIA; THORAX RADIOGRAPHY;

ADULT; BIOPSY; FEMALE; GIANT CELLS; HEART-ASSIST DEVICES; HEMODYNAMICS; HUMANS; MYOCARDITIS; PROSTHESIS DESIGN; RECOVERY OF FUNCTION; SHOCK, CARDIOGENIC; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 80051710401     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med 1997;336(26):1860-6.
2. Desjardins V, Pelletier G, Leung TK, Waters D. Successful treatment of severe heart failure caused by idiopathic giant cell myocarditis. Can J Cardiol 1992;8(8):788-92.
3. Levy NT, Olson LJ, Weyand C, Brack A, Tazelaar HD, Edwards WD, Hammill SC. Histologic and cytokine response to immunosuppression in giant-cell myocarditis. Ann Intern Med 1998;128(8):648-50.
4. Cooper LT Jr. Giant cell myocarditis: diagnosis and treatment. Herz 2000;25(3):291-8.
5. Kodama M, Hanawa H, Saeki M, Hosono H, Inomata T, Suzuki K, Shibata A. Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res 1994;75(2):278-84.
6. Kodama M, Matsumoto Y, Fujiwara M, Masani F, Izumi T, Shibata A. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol 1990;57(2):250-62.
7. Litovsky SH, Burke AP, Virmani R. Giant cell myocarditis: an entity distinct from sarcoidosis characterized by multiphasic myocyte destruction by cytotoxic T cells and histiocytic giant cells. Mod Pathol 1996;9(12):1126-34.
8. LaRocca GM, Shimbo D, Rodriguez CJ, Stewart A, Naka Y, Weinberger J, et al. The Impella Recover LP 5.0 left ventricular assist device: a bridge to coronary artery bypass grafting and cardiac transplantation. J Am Soc Echocardiogr 2006;19 (4):468.e5-7.
9. Seyfarth M, Sibbing D, Bauer I, Frohlich G, Bott-Flugel L, Byrne R, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 2008;52(19):1584-8.
10. Siegenthaler MP, Brehm K, Strecker T, Hanke T, Notzold A, Olschewski M, et al. The Impella Recover microaxial left ventricular assist device reduces mortality for postcardiotomy failure: a three-center experience. J Thorac Cardiovasc Surg 2004;127(3):812-22.
11. Henriques JP, Remmelink M, Baan J Jr, van der Schaaf RJ, Vis MM, Koch KT, et al. Safety and feasibility of elective high-risk percutaneous coronary intervention procedures with left ventricular support of the Impella Recover LP 2.5. Am J Cardiol 2006;97(7):990-2.